Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

In patients with atrial fibrillation, those assigned left atrial appendage closure had similar ischemic outcomes and better bleeding outcomes compared with those assigned oral anticoagulation, ...

Claire Cramer, the executive director of quantum science at the University of California, Berkeley, who was in attendance, expressed optimism about the potential of solid-state nuclear clocks: “This ...